Saluda Medical Statistics
Total Valuation
Saluda Medical has a market cap or net worth of AUD 320.07 million. The enterprise value is 899.19 million.
| Market Cap | 320.07M |
| Enterprise Value | 899.19M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Saluda Medical has 252.02 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 252.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.13 |
| PB Ratio | 7.11 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.13 |
| EV / Sales | 11.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.36 |
Financial Position
The company has a current ratio of 5.38, with a Debt / Equity ratio of 2.39.
| Current Ratio | 5.38 |
| Quick Ratio | 3.82 |
| Debt / Equity | 2.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.76 |
| Interest Coverage | -19.82 |
Financial Efficiency
Return on equity (ROE) is -127.42% and return on invested capital (ROIC) is -42.33%.
| Return on Equity (ROE) | -127.42% |
| Return on Assets (ROA) | -36.61% |
| Return on Invested Capital (ROIC) | -42.33% |
| Return on Capital Employed (ROCE) | -93.86% |
| Revenue Per Employee | 582,413 |
| Profits Per Employee | -1.10M |
| Employee Count | 133 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.25 |
Taxes
In the past 12 months, Saluda Medical has paid 409,172 in taxes.
| Income Tax | 409,172 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,782,358 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Saluda Medical had revenue of AUD 77.46 million and -146.62 million in losses. Loss per share was -0.88.
| Revenue | 77.46M |
| Gross Profit | 34.64M |
| Operating Income | -148.59M |
| Pretax Income | -146.21M |
| Net Income | -146.62M |
| EBITDA | -145.76M |
| EBIT | -148.59M |
| Loss Per Share | -0.88 |
Balance Sheet
The company has 107.60 million in cash and 107.59 million in debt, giving a net cash position of 10,492 or 0.00 per share.
| Cash & Cash Equivalents | 107.60M |
| Total Debt | 107.59M |
| Net Cash | 10,492 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 45.05M |
| Book Value Per Share | -3.19 |
| Working Capital | 142.66M |
Cash Flow
In the last 12 months, operating cash flow was -139.87 million and capital expenditures -1.62 million, giving a free cash flow of -141.49 million.
| Operating Cash Flow | -139.87M |
| Capital Expenditures | -1.62M |
| Free Cash Flow | -141.49M |
| FCF Per Share | -0.56 |
Margins
Gross margin is 44.72%, with operating and profit margins of -191.82% and -189.29%.
| Gross Margin | 44.72% |
| Operating Margin | -191.82% |
| Pretax Margin | -188.76% |
| Profit Margin | -189.29% |
| EBITDA Margin | -188.17% |
| EBIT Margin | -191.82% |
| FCF Margin | n/a |
Dividends & Yields
Saluda Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -45.81% |
| FCF Yield | -44.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Saluda Medical has an Altman Z-Score of -5.94 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.94 |
| Piotroski F-Score | 1 |